Phaseline

Companies › Shanghai World Leader Pharmaceutical

Shanghai World Leader Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Semaglutide (WL1006)
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 1Overweight–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07465965Semaglutide (WL1006)Phase 1OverweightMetabolic and endocrineAug 2026

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.